125 related articles for article (PubMed ID: 9683814)
21. Efficient synthesis of cryptophycin-52 and novel para-alkoxymethyl unit A analogues.
Eissler S; Bogner T; Nahrwold M; Sewald N
Chemistry; 2009 Oct; 15(42):11273-87. PubMed ID: 19760734
[TBL] [Abstract][Full Text] [Related]
22. Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells.
Lu K; Dempsey J; Schultz RM; Shih C; Teicher BA
Cancer Chemother Pharmacol; 2001; 47(2):170-8. PubMed ID: 11269744
[TBL] [Abstract][Full Text] [Related]
23. Conformational changes in tubulin upon binding cryptophycin-52 reveal its mechanism of action.
Eren E; Watts NR; Sackett DL; Wingfield PT
J Biol Chem; 2021 Oct; 297(4):101138. PubMed ID: 34461087
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of macromolecular synthesis by cryptophycin-52.
Subramanian B; Nakeff A; Media JE; Wiegand RA; Valeriote FA
Anticancer Drugs; 2002 Nov; 13(10):1061-8. PubMed ID: 12439340
[TBL] [Abstract][Full Text] [Related]
25. Novel cryptophycin antitumor agents: synthesis and cytotoxicity of fragment "B" analogues.
Patel VF; Andis SL; Kennedy JH; Ray JE; Schultz RM
J Med Chem; 1999 Jul; 42(14):2588-603. PubMed ID: 10411479
[TBL] [Abstract][Full Text] [Related]
26. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703.
De Pas TM; Mandalà M; Curigliano G; Peccatori F
Obstet Gynecol; 2000 Jun; 95(6 Pt 2):1030. PubMed ID: 10808018
[No Abstract] [Full Text] [Related]
27. Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region).
Varie DL; Shih C; Hay DA; Andis SL; Corbett TH; Gossett LS; Janisse SK; Martinelli MJ; Moher ED; Schultz RM; Toth JE
Bioorg Med Chem Lett; 1999 Feb; 9(3):369-74. PubMed ID: 10091686
[TBL] [Abstract][Full Text] [Related]
28. Three new cryptophycins from Nostoc sp. GSV 224.
Subbaraju GV; Golakoti T; Patterson GM; Moore RE
J Nat Prod; 1997 Mar; 60(3):302-5. PubMed ID: 9090872
[TBL] [Abstract][Full Text] [Related]
29. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.
Chou TC; Zhang XG; Harris CR; Kuduk SD; Balog A; Savin KA; Bertino JR; Danishefsky SJ
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15798-802. PubMed ID: 9861050
[TBL] [Abstract][Full Text] [Related]
30. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
31. Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors.
Liang J; Moore RE; Moher ED; Munroe JE; Al-awar RS; Hay DA; Varie DL; Zhang TY; Aikins JA; Martinelli MJ; Shih C; Ray JE; Gibson LL; Vasudevan V; Polin L; White K; Kushner J; Simpson C; Pugh S; Corbett TH
Invest New Drugs; 2005 Jun; 23(3):213-24. PubMed ID: 15868377
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of cryptophycin 52 using the Shi epoxidation.
Hoard DW; Moher ED; Martinelli MJ; Norman BH
Org Lett; 2002 May; 4(10):1813-5. PubMed ID: 12000306
[TBL] [Abstract][Full Text] [Related]
34. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and cytotoxicity studies of new cryptophycin analogues.
Liu WL; Zhang JC; Jiang FQ; Fu L
Arch Pharm (Weinheim); 2009 Oct; 342(10):577-83. PubMed ID: 19714674
[TBL] [Abstract][Full Text] [Related]
36. Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jan; 47(3):696-702. PubMed ID: 14736249
[TBL] [Abstract][Full Text] [Related]
37. Sensitive determination of plasma protein binding of cationic drugs using mixed-mode solid-phase microextraction.
Peltenburg H; Bosman IJ; Hermens JL
J Pharm Biomed Anal; 2015 Nov; 115():534-42. PubMed ID: 26313333
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2.
Romanini A; Sobrero AF; Chou TC; Sherwood RF; Bertino JR
Cancer Res; 1989 Nov; 49(21):6019-23. PubMed ID: 2529027
[TBL] [Abstract][Full Text] [Related]
39. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
40. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
Weiss C; Figueras E; Borbely AN; Sewald N
J Pept Sci; 2017 Jul; 23(7-8):514-531. PubMed ID: 28661555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
